6533b839fe1ef96bd12a6410
RESEARCH PRODUCT
The role of second and third line tyrosine kinase inhibitor monotherapy in EGFR wild-type (and unknown mutational status) advanced non-small-cell lung cancer patients: Findings from a retrospective analysis
R. AlessandroGiovanni SortinoSergio RizzoFrancesco PassigliaL. BlasiTindara FranchinaAntonio PiconeM. AlùL. AgataAlessandro RussoClaudia CelesiaS. GiuseppinaVincenzo AdamoGiuseppe Brontesubject
Oncologymedicine.medical_specialtybusiness.industrymedicine.drug_classWild typeHematologymedicine.diseaseTyrosine-kinase inhibitorOncologyThird lineInternal medicinemedicineRetrospective analysisMutational statusNon small cellbusinessLung canceryear | journal | country | edition | language |
---|---|---|---|---|
2015-10-01 | Annals of Oncology |